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The Authors Reply: We thank Daugirdas for his comments
in ‘Proposed controlled trials of phosphate reduction in CKD:
which whey should we go?’1 We agree that reducing dietary
phosphorus intake is an important strategy to control
phosphorus balance in renal failure that is worthy of testing
in randomized trials. Daugirdas’s interesting approach would
effectively dissociate phosphorus restriction from undesirable
protein restriction through the use of whey supplements and
through avoidance of foods with high phosphorus-to-protein
ratios, such as processed foods. In support of this proposal,
the feasibility of dietary counseling to reduce serum
phosphate levels in dialysis patients has been established by
a recent randomized trial.2 It is likely, however, that several
factors could limit the effectiveness and sustainability of
dietary phosphorus restriction alone. First, the lack of
accurate labeling of phosphorus content in food additives
and its inconsistency across speciﬁc manufacturers3 compli-
cates dietary counseling. Second, while the cost of whey may
be low, effective ongoing dietary counseling requires dedi-
cated and relatively costly nutritionists. Perhaps most
importantly, kidney disease is largely a disease of poverty,
which, under the strain of the recession, is deepening in the
United States. Impoverished dialysis patients, even those most
successfully counseled, will likely forgo healthy food choices
in favor of cheap prepared foods that are phosphorus-laden
and widely available. To beneﬁt the majority of patients, we
would therefore suggest a multipronged approach to reduce
phosphate levels in dialysis patients, involving both pharma-
ceutical and dietary interventions as suggested by Daugirdas.
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Non-infected hemodialysis
catheters are associated with
increased inflammation compared
with arteriovenous fistulas
To the Editor: We read with great interest the article by
Goldstein et al.,1 reporting that catheters may cause
inﬂammation independent of infection as compared with
arteriovenous (AV) ﬁstula use. The authors showed greater
levels of serum C-reactive protein (CRP) in patients dialyzed
with central catheters in contrast to AV ﬁstulas.
We wish to highlight a few important points. First, the
authors did not give any information about comorbidity status,
underlying primary renal disease, level of uremia, glycemic
control of diabetic patients, echocardiographic data, anthro-
pometric measures, or prealbumin and cholesterol concentra-
tions showing nutritional status and residual renal function
(RRF) at the start of hemodialysis. It is known that CRP is
affected not only by infection but also by many variables, such
as RRF, coronary heart disease, peripheral arterial disease,
malnutrition, and metabolic syndrome.2,3 Thus, it is very
difﬁcult to attribute high CRP levels solely to the presence of a
catheter unless these variables are appropriately controlled for.
Second, the authors measured only serum CRP concentra-
tions, did not include other inﬂammation markers, and took
measurements just twice in a 6-month period. CRP levels,
especially in the hemodialysis population, may ﬂuctuate; thus,
obtaining single CRP measurements may be misleading.4
Third, the catheter group involved desperate patients in
whom ﬁstula attempt had failed. Thus, there was no option
other than catheter use, of course after trying the ﬁstula at a
more proximal site and vascular grafts. The advantages of the
‘ﬁstula ﬁrst’ slogan have long been established for naive
patients. Hence, a call for ﬁstula ﬁrst for patients with failed
ﬁstulas seems inappropriate.
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The Authors Reply: We thank Drs Solak and Atalay1 for
their interest in our work.2 With regard to their ﬁrst
comment, we reported data about diabetes, age, and gender,
and adjusted for these factors. More importantly, we adjusted
for phosphorus level—a well-known factor for cardiovascular
morbidity and mortality in dialysis patients.3 Furthermore, we
excluded patients with a failed renal allograft or clotted,
arteriovenous graft in place—two well-known causes of
inﬂammation.4,5 Finally, 47 of 50 patients in the ﬁstula-
catheter group had urine output less than 200ml at the
initiation of dialysis.
With regard to inﬂammatory markers, C-reactive protein
(CRP) is the most commonly assessed marker in dialysis
studies; we had other evidence of inﬂammation (lower
hematocrit and albumin, higher Erythropoiesis Resistance
Index) in catheter patients. In addition, although CRP can
ﬂuctuate, in all cases, the mean (s.d.) CRP levels did not
overlap between ﬁstula and catheter patients at any time
point, suggesting a strong association between CRP and
access. Additional markers, such as IL-6, may provide more
speciﬁcity, but would not have altered the interpretation of
our data. Finally, the last comment is incorrect—all patients
had ﬁstula placement as an elective procedure; catheters were
never placed as a ‘desperate’ attempt, but were used as
vascular access until ﬁstula maturation.
Thus, we believe our data support the role of a non-
infected dialysis catheter as the sole cause of inﬂammation.
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The CANUSA study and
the importance of residual
kidney function in dialysis
patients
To the Editor: I read with much interest the mini-review by
Rosansky et al.1 that examined the implications of starting
dialysis at a higher glomerular ﬁltration rate (GFR). There
were a couple of inaccurate statements that need to be
corrected for your readers.
The authors describe the Canada –USA Peritoneal Dialysis
Study Group study as ‘an observational study that suggested a
potential beneﬁt on renal survival of a weekly peritoneal
creatinine clearance of 470 l/1.73m2.’ The beneﬁt of that
clearance value was for survival of the patient, not for renal
survival.
In the same paragraph is the following: ‘In addition,
although the Canada – USA Peritoneal Dialysis Study Group
study supported a relationship between the level of peritoneal
clearance and survival, one can argue that the RKF in these
continuous ambulatory peritoneal dialysis patients was
primarily responsible for the survival advantage.’ One could
indeed argue this, and it was exactly this ﬁnding that was
reported in the re-analysis of the Canada – USA Peritoneal
Dialysis Study Group study.2 In this re-analysis, the small
solute clearance parameters were subdivided into the
peritoneal and renal contribution. The peritoneal clearance
had no predictive power on patient survival, whereas every
5 l/week of residual GFR was associated with a 12% reduction
in mortality. Urine volume was an even more powerful
predictor of outcome, with every 250ml/day associated with a
36% reduction in mortality.2
We need to avoid becoming so obsessed with small solute
kinetics that we forget about the importance of residual
kidney function in our dialysis patients.
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The Authors Reply: We strongly agree with Dr Bargman’s1
reference to the importance of residual kidney function in the
decision to start dialysis. In fact, the assumptions used to
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